More molecular glue: Plexium pens AbbVie pact months after Amgen deal

A few months after its deal with Amgen, San Diego-based biotech Plexium has inked a deal with another Big Pharma – this time, it’s AbbVie.

While Amgen’s deal focused on the cancer space, AbbVie hopes to use Plexium’s “agnostic” targeted protein degradation (TPD) platform to screen for new therapies for neurological diseases, Plexium announced today.